Portfolio Expansion

About Veriton Pharma

Veriton Pharma is a specialised pharmaceutical company, acquired by SERB Pharmaceuticals in 2020, that develops and commercialises tailored therapies for unmet medical needs, with a core focus on CNS disorders like epilepsy and rare paediatric conditions. It operates a hybrid portfolio of licensed prescription products and a broad range of unlicensed 'specials', supported by a trusted supply chain and direct NHS engagement. The company benefits from SERB's global infrastructure and antidote portfolio, positioning it as a key player in niche therapeutic areas with a strong service-oriented model for hospitals and prescribers worldwide.

About YARAL Pharma

YARAL Pharma is a private, commercial-stage generics company founded in 2019 and headquartered in San Diego, California. As the U.S. arm of IBSA, it leverages its parent company's manufacturing expertise and pipeline to commercialize authorized generics in therapeutic areas like pain and endocrinology, with plans to expand into dermatology and reproductive medicine. The company's strategy centers on ensuring supply continuity, forming strategic partnerships, and providing smarter solutions within the generic drug market to enhance healthcare outcomes.

Therapeutic Areas